| Literature DB >> 26497027 |
Janet MacNeil Vroomen1, Iris Eekhout2, Marcel G Dijkgraaf2, Hein van Hout2, Sophia E de Rooij2, Martijn W Heymans2, Judith E Bosmans2.
Abstract
Cost and effect data often have missing data because economic evaluations are frequently added onto clinical studies where cost data are rarely the primary outcome. The objective of this article was to investigate which multiple imputation strategy is most appropriate to use for missing cost-effectiveness data in a randomized controlled trial. Three incomplete data sets were generated from a complete reference data set with 17, 35 and 50 % missing data in effects and costs. The strategies evaluated included complete case analysis (CCA), multiple imputation with predictive mean matching (MI-PMM), MI-PMM on log-transformed costs (log MI-PMM), and a two-step MI. Mean cost and effect estimates, standard errors and incremental net benefits were compared with the results of the analyses on the complete reference data set. The CCA, MI-PMM, and the two-step MI strategy diverged from the results for the reference data set when the amount of missing data increased. In contrast, the estimates of the Log MI-PMM strategy remained stable irrespective of the amount of missing data. MI provided better estimates than CCA in all scenarios. With low amounts of missing data the MI strategies appeared equivalent but we recommend using the log MI-PMM with missing data greater than 35 %.Entities:
Keywords: Cost data; Economic evaluation; Missing data; Multiple imputation
Mesh:
Substances:
Year: 2015 PMID: 26497027 PMCID: PMC5047955 DOI: 10.1007/s10198-015-0734-5
Source DB: PubMed Journal: Eur J Health Econ ISSN: 1618-7598
Baseline characteristics of the reference data set
| Explanatory variables | Methadone alone ( | Co-prescribed heroin ( |
|---|---|---|
| % Male ( | 55.1 (190) | 44.9 (155) |
| Age (SD) | 38.9 (5.7) | 39.7 (5.8) |
| % Injected ( | 56.3 (98) | 43.7 (76) |
| % Completed ( | 60.2 (204) | 39.8 (135) |
| % Abstinent ( | 59.3 (80) | 40.7 (55) |
| % Second interview performed ( | 55.7 (59) | 44.3 (47) |
| Baseline utility (SD) | 0.731 (0.273) | 0.739 (0.272) |
aThose included early in the trials also completed the questionnaire in the second month. SD standard deviation. Figures are frequencies (column percent)
Descriptive statistics of the cost variables (euros) for the reference data set and the data sets with missing values
| Description | QALY [ | Travel costs | Total programme costs | Out-of-hospital consult costs | In-patient hospital consult costs | In-patient hospital stay costs | Police investigations of criminal offenders costs | Convicting criminal offenders costs | Sanctioning criminal offenders costs | Damage to victims costs |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Mean cost (euros) | 0.76 | 350.04 | 8692.99 | 45.97 | 316.12 | 778.96 | 6004.28 | 3172.95 | 1854.53 | 23,602.36 |
| Standard deviation | 0.22 | 292.79 | 10,315.04 | 124.06 | 1206.92 | 3680.04 | 14,497.13 | 12,627.55 | 5935.78 | 59,945.50 |
| Percentage of zeroes | N/A | 3.3 | 0.2 | 67.4 | 56.7 | 91.6 | 58.4 | 88.8 | 77.2 | 71.2 |
| Skewness | −1.28 | 0.90 | 0.93 | 4.81 | 10.39 | 7.32 | 7.10 | 6.14 | 4.20 | 3.17 |
|
| ||||||||||
| Mean cost (euros) | 0.75 | 350.04 | 8266.09 | 43.89 | 323.21 | 727.68 | 6304.52 | 3260.05 | 1751.09 | 24,391.48 |
| Standard deviation | 0.23 | 292.79 | 10,022.88 | 109.55 | 1267.93 | 3446.62 | 15,219.27 | 12,995.47 | 5797.58 | 61,348.19 |
| Percentage of zeroes | N/A | 3.3 | 0.3 | 67.2 | 58.1 | 91.8 | 58.9 | 88.9 | 77.8 | 71.0 |
| Skewness | −1.30 | 0.90 | 0.99 | 3.95 | 10.01 | 7.36 | 6.81 | 6.06 | 4.45 | 3.14 |
|
| ||||||||||
| Mean cost (euros) | 0.75 | 350.04 | 8218.24 | 44.99 | 336.41 | 794.57 | 6462.09 | 3027.35 | 1731.97 | 24,611.35 |
| Standard deviation | 0.23 | 292.79 | 10,075.05 | 112.93 | 1318.40 | 3711.62 | 15,665.51 | 12,569.37 | 5783.11 | 62,221.27 |
| Percentage of zeroes | N/A | 3.3 | 0.3 | 66.0 | 57.4 | 91.6 | 58.8 | 89.6 | 78.1 | 70.7 |
| Skewness | −1.23 | 0.90 | 1.02 | 4.00 | 9.69 | 7.09 | 6.75 | 6.40 | 4.56 | 3.17 |
|
| ||||||||||
| Mean cost (euros) | 0.74 | 350.04 | 7907.28 | 49.09 | 338.09 | 853.85 | 6523.91 | 2586.35 | 1749.48 | 23,280.58 |
| Standard deviation | 0.23 | 292.79 | 9995.16 | 118.29 | 1357.34 | 3972.24 | 15,794.79 | 11,541.70 | 5873.06 | 60,485.85 |
| Percentage of zeroes | N/A | 3.3 | 0.3 | 63.7 | 57.7 | 91.0 | 57.7 | 90.5 | 78.2 | 72.5 |
| Skewness | −1.20 | 0.90 | 1.11 | 3.82 | 9.60 | 7.00 | 6.99 | 7.31 | 4.58 | 3.27 |
N/A not applicable
Overview of cost estimates for the missing data methods
| RA | CCA (% bias) | MI-PMM (% bias) | Log MI-PMM (% bias) | Two-step MI (% bias) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M | M + H | M | M + H | M | M + H | M | M + H | M | M + H | |
|
| ||||||||||
|
| 237 | 193 | 201 | 154 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean cost (euros) | 50,560 | 37,767 | 53,148 | 38,933 | 51,369 | 37,935 | 51,966 | 38,137 | 52,685 | 38,482 |
| SE mean (euros) | 5359 | 3063 | 6056 | 3744 | 5650 | 3268 | 5652 | 3309 | 5642 | 3394 |
| Treatment cost difference (euros) | −12,792 | −14,215 (11) | −13,434 (5) | −13,829 (8) | −13,203 (3) | |||||
| SE cost difference | 6086 | 7077 (14) | 6440 (5) | 6459 (5) | 6506 (6) | |||||
|
| −2.100 | −2.010 | −2.090 | −2.140 | −2.030 | |||||
|
| 0.036 | 0.045 | 0.037 | 0.032 | 0.042 | |||||
| 95 % CI lower limit | −24,720 | −28,085 | −26,057 | −26,489 | −25,954 | |||||
| 95 % CI upper limit | −865 | −345 | −810 | −1169 | −452 | |||||
|
| ||||||||||
|
| 237 | 193 | 163 | 122 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean cost (euros) | 50,560 | 37,767 | 52,255 | 43,176 | 50,810 | 39,851 | 51,434 | 40,408 | 51,195 | 40,426 |
| SE mean (euros) | 5359 | 3063 | 6953 | 4560 | 5989 | 3448 | 5975 | 3601 | 6052 | 3551 |
| Treatment cost difference (euros) | −12,792 | −9080 (29) | −10,959 (14) | −11,026 (16) | −10,769 (16) | |||||
| SE cost difference | 6086 | 8463 (39) | 6853 (13) | 6988 (15) | 6954 (14) | |||||
|
| −2.100 | −1.070 | −1.600 | −1.580 | −1.550 | |||||
|
| 0.036 | 0.283 | 0.110 | 0.115 | 0.122 | |||||
| 95 % CI lower limit | −24,720 | −25,667 | −24,393 | −24,725 | −24,400 | |||||
| 95 % CI upper limit | −865 | 7508 | 2475 | 2673 | 2862 | |||||
|
| ||||||||||
|
| 237 | 193 | 132 | 91 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean cost (euros) | 50,560 | 37,767 | 50,160 | 42,794 | 48,711 | 38,335 | 49,180 | 38,527 | 49,110 | 39,454 |
| SE mean (euros) | 5359 | 3063 | 7447 | 5336 | 5875 | 3513 | 5857 | 3501 | 5913 | 3683 |
| Treatment cost difference (euros) | −12,792 | −7366 (42) | −10,376 (19) | −10,653 (17) | −9656 (25) | |||||
| SE cost difference | 6086 | 9496 (56) | 6852 (13) | 6764 (11) | 6954 (14) | |||||
|
| −2.100 | −0.780 | −1.510 | −1.570 | −1.390 | |||||
|
| 0.036 | 0.438 | 0.130 | 0.115 | 0.165 | |||||
| 95 % CI lower limit | −24,720 | −25,978 | −23,810 | −23,912 | −23,289 | |||||
| 95 % CI upper limit | −865 | 11,246 | 3058 | 2607 | 3977 | |||||
M refers to the methadone maintenance treatment group, M + H refers to the group that had medical co-prescription of heroin. SE standard error, CI confidence interval, RA reference analysis, CCA complete case analysis, PMM multiple imputation with predictive mean matching, Log MI-PMM multiple imputation with predictive mean matching on log-transformed costs, Two-step-MI two-step multiple imputation with predictive mean matching
Overview clinical effect estimates of QALY model for the missing data methods
| RA | CCA (% bias) | MI-PMM (% bias) | Log MI-PMM (% bias) | Two-step MI (% bias) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M | M + H | M | M + H | M | M + H | M | M + H | M | M + H | |
|
| ||||||||||
|
| 237 | 193 | 201 | 154 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean (QALY) | 0.730 | 0.798 | 0.722 | 0.798 | 0.728 | 0.792 | 0.727 | 0.791 | 0.728 | 0.792 |
| SE mean (QALY) | 0.015 | 0.016 | 0.017 | 0.016 | 0.016 | 0.016 | 0.016 | 0.016 | 0.020 | 0.016 |
| QALY difference | 0.054 | 0.060 (11) | 0.061 (12) | 0.061 (12) | 0.061 (12) | |||||
| SE QALY difference | 0.018 | 0.020 (12) | 0.020 (10) | 0.020 (10) | 0.020 (11) | |||||
|
| 2.970 | 2.950 | 3.020 | 3.020 | 3.000 | |||||
|
| 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | |||||
| 95 % CI lower limit | 0.018 | 0.020 | 0.021 | 0.021 | 0.021 | |||||
| 95 % CI upper limit | 0.090 | 0.100 | 0.100 | 0.100 | 0.100 | |||||
|
| ||||||||||
|
| 237 | 193 | 163 | 122 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean (QALY) | 0.730 | 0.790 | 0.715 | 0.790 | 0.718 | 0.790 | 0.717 | 0.791 | 0.718 | 0.790 |
| SE mean (QALY) | 0.015 | 0.018 | 0.020 | 0.018 | 0.017 | 0.016 | 0.017 | 0.016 | 0.017 | 0.016 |
| QALY difference | 0.054 | 0.068 (24) | 0.069 (27) | 0.071 (30) | 0.069 (27) | |||||
| SE QALY difference | 0.018 | 0.023 (27) | 0.021 (17) | 0.022 (18) | 0.022 (20) | |||||
|
| 2.970 | 2.910 | 3.230 | 3.260 | 3.150 | |||||
|
| 0.003 | 0.004 | 0.001 | 0.001 | 0.002 | |||||
| 95 % CI lower limit | 0.018 | 0.022 | 0.027 | 0.028 | 0.026 | |||||
| 95 % CI upper limit | 0.090 | 0.113 | 0.111 | 0.113 | 0.112 | |||||
|
| ||||||||||
|
| 237 | 193 | 132 | 91 | 237 | 193 | 237 | 193 | 237 | 193 |
| Mean (QALY) | 0.730 | 0.782 | 0.717 | 0.782 | 0.705 | 0.785 | 0.708 | 0.784 | 0.706 | 0.784 |
| SE mean (QALY) | 0.015 | 0.021 | 0.021 | 0.021 | 0.018 | 0.017 | 0.018 | 0.018 | 0.018 | 0.018 |
| QALY difference | 0.054 | 0.047 (13) | 0.077 (41) | 0.074 (36) | 0.075 (38) | |||||
| SE QALY difference | 0.018 | 0.026 (43) | 0.024 (29) | 0.024 (30) | 0.024 (31) | |||||
|
| 2.970 | 1.820 | 3.260 | 3.110 | 3.140 | |||||
|
| 0.003 | 0.069 | 0.001 | 0.002 | 0.002 | |||||
| 95 % CI lower limit | 0.018 | −0.004 | 0.031 | 0.027 | 0.028 | |||||
| 95 % CI upper limit | 0.090 | 0.098 | 0.123 | 0.120 | 0.122 | |||||
M refers to the methadone maintenance treatment group, M + H refers to the group that had medical co-prescription of heroin. SE standard error, QALY quality of life years gained, CI confidence interval, RA reference analysis, CCA complete case analysis, PMM multiple imputation with predictive mean matching, Log MI-PMM multiple imputation with predictive mean matching on log-transformed costs, Two-step-MI two-step multiple imputation with predictive mean matching
Fig. 1Incremental net benefit (in euros) coefficients for a threshold value of €30,000 based on the amount of missing data and imputation method. MI-PMM multiple imputation with predictive mean matching, log-MI-PMM multiple imputation with predictive mean matching on log-transformed costs, MI-PMM 2 step two-step multiple imputation with predictive mean matching
Cost effectiveness analysis estimates for the missing data methods
| RA | CCA (% bias) | MI-PMM (% bias) | Log MI-PMM (% bias) | Two-step MI (% bias) | |
|---|---|---|---|---|---|
|
| |||||
| Correlation utility and costs | 0.0507 | 0.0591 | 0.0517 | 0.0509 | 0.0487 |
| Covariance | 5.6 | 8.6 | 6.7 | 6.6 | 6.4 |
| Mean (INB) | 14,422 | 16,026 (11) | 15,257 (6) | 15,654 (9) | 15,023 (4) |
| SE INB | 6083 | 7270 (20) | 6438 (6) | 6457 (6) | 6504 (7) |
| 95 % CI lower limit | 4417 | 4069 | 4669 | 5034 | 4324 |
| 95 % CI upper limit | 24,427 | 27,983 | 25,846 | 26,274 | 25,721 |
| Prob C-E | 0.99 | 0.99 (0) | 0.99 (0) | 0.99 (0) | 0.99 (0) |
| ICER | −235,472 | −235,448 (0) | −220,988 (6) | −227,410 (3) | −217,656 (8) |
|
| |||||
| Correlation utility and costs | 0.0507 | 0.0251 | 0.0300 | 0.0292 | 0.028 |
| Covariance | 5.6 | 4.9 | 4.4 | 4.4 | 4.4 |
| Mean (INB) | 14,422 | 11,105 (23) | 13,029 (10) | 13,143 (9) | 12,841 (11) |
| SE (INB) | 6083 | 8685 (43) | 6864 (13) | 7000 (15) | 6966 (15) |
| 95 % CI lower limit | 4417 | −3181 | 1738 | 1629 | 1383 |
| 95 % CI upper limit | 24,427 | 25,390 | 24,319 | 24,656 | 24,299 |
| Prob C-E | 0.99 | 0.90 (9) | 0.97 (2) | 0.97 (2) | 0.97 (2) |
| ICER | −235,472 | −134,488 (43) | −158,857 (33) | −156,289 (34) | −155,935 (34) |
|
| |||||
| Correlation utility and costs | 0.0507 | 0.0223 | 0.0433 | 0.0436 | 0.0406 |
| Covariance | 5.6 | 5.5 | 7.0 | 7.0 | 6.7 |
| Mean (INB) | 14,422 | 8786 (39) | 12,682 (12) | 12,867 (11) | 11,907 (17) |
| SE (INB) | 6083 | 9584 (58) | 6858 (13) | 6770 (11) | 6962 (14) |
| 95 % CI lower limit | 4417 | −6978 | 1401 | 1731 | 456 |
| 95 % CI upper limit | 24,427 | 24,551 | 23,962 | 24,003 | 23,358 |
| Prob C-E | 0.99 | 0.82 (17) | 0.97 (2) | 0.97 (2) | 0.96 (3) |
| ICER | −235,472 | −155,561 (34) | −134,979 (43) | −144,317 (39) | −128,670 (45) |
SE standard error, INB incremental net benefit (euros), CI confidence interval, Prob C-E probability of cost-effectiveness, ICER incremental cost effectiveness ratio
Fig. 2Cost-effectiveness acceptability curves for threshold value of €30,000 based on the 50 % missing data scenario. PMM Multiple imputation with predictive mean matching, Log multiple imputation with predictive mean matching on log-transformed costs, 2step two-step multiple imputation with predictive mean matching